Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.78, $0.08 better than the analyst estimate of $0.70. Revenue for the quarter came in at $168.1 million versus the consensus estimate of $168.07 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.